On August 26, 2018, Nevada-based GB Sciences, Inc. (OTC: GBLX) selected New Jersey-based Catalent Pharma Solutions, a leading global provider of delivery technologies for drugs, provide oral delivery systems, formulation development, and manufacturing of its ingredients for its Parkinson’s disease therapies.
Catalent will conduct a proof of concept study at its U.K. facility to evaluate GB Sciences’ clinical candidates using Catalent’s Zydis® Orally Disintegrating Tablet.
GB Sciences’ three patent-pending drugs for Parkinson’s are mixtures containing up to nine CBD components. Studies have shown these mixtures are more potent together than individually.
GB Sciences selected Catalent due to its expertise in tackling formulation challenges, and the ability to achieve the stability and dosing necessary. They were specifically interested in Catalent’s orally disintegrating tablets, which would be easier for Parkinson’s patients who may have trouble swallowing.
Catalent is a leading global provider of delivery technologies for drugs, biologics and consumer health products. It employs 11,000 people, including 1,800 scientists, at over 30 facilities on five continents. In fiscal 2018 it generated $2.5 billion in revenue.
GB Sciences, Inc. (OTC: GBLX) is a diverse cannabis company, focused on cultivation and biopharmaceutical R&D. Its goal is creating pharmaceutical-grade, CBD therapies for several medical conditions.
Source: GB press release
{{cta(‘b491434f-c6aa-4547-b3d4-6a7293c8ad67’)}}